The chief of the lymphoma division and oncologist at Levine Cancer Institute discussed data from real-world experience studies.
The approval builds off of liso-cel's (Breyanzi) previous indication for third-line or later treatment in LBCL.
Review top news and interview highlights from the week ending June 24, 2022.
BioMarin received a positive CHMP opinion after the FDA delayed val-rox's BLA filing for the second time.
B-VEC recently showed efficacy in the phase 3 GEM-3 trial.
The director of the Pediatric Hemophilia and Coagulation Disorders Program at CS Mott Children’s Hospital discussed common challenges with gene therapy clinical trials.